| 99284 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making. | 22 | 150 | 7,400 | $170 | $2.8M |
| 99283 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a low level of medical decision making. | 31 | 140 | 10,160 | $130 | $2.3M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 6 | 10 | 1,790 | $60 | $1.8M |
| 81420 | The lab analyst performs a genomic sequence analysis panel to evaluate circulating cell free fetal DNA in maternal blood for genetic sequences of at least the genes on chromosomes 13, 18, and 21,… | 2 | 10 | 1,200 | $690 | $770.6K |
| 41899 | Use this code to report a procedure on the teeth and adjoining alveolar structures for which there is no specific code available. | 8 | 20 | 190 | $1,070 | $556K |
| 99499 | Use 99499 to report evaluation and management services for which there is no specific code available. | 9 | 10 | 110 | $910 | $468.7K |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 9 | 10 | 100 | $1,160 | $435.3K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 10 | 60 | 420 | $60 | $405.1K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 11 | 20 | 470 | $460 | $398.7K |
| 92507 | The provider treats a patient with communication and hearing difficulties by directly interacting with the patient. He assesses the patient with impairment in his ability to make sounds, along with… | 59 | 80 | 1,420 | $60 | $368.8K |